With respect to South Korea, Novartis fixed sure effectively-publicized allegations that it experienced made incorrect payments to HCPs in South Korea through round tables and 3rd-bash clinical journals. Novartis Korea allegedly transmitted improper honoraria to HCPs for spherical tables through health-related journals to prevent compliance scrutin